Fig. 1
From: Mode and site of action of therapies targeting CGRP signaling
Anti-CGRP drugs and their peripheral sites of action in the trigeminovascular system. Schematic of CGRP-based therapies highlighting where the CGRP monoclonal antibodies (mAbs), CGRP receptor mAbs, and CGRP receptor antagonists (gepants) have their main site of action. The expression of AMY1 receptors remains to be fully determined. Adapted from [12, 21]